Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if tremelimumab in combination with
MEDI4736, FOLFOX (fluorouracil, leucovorin, and oxaliplatin), and bevacizumab can help to
control colorectal cancer that has spread to the liver. The safety of these drugs will also
be studied.